Table 1.
Tests of associations between KM, GM, and FcγR variants and anti-EGFR antibody levels (AU/µL) in patients with glioblastoma
| Loci | Genotype | N | Anti-EGFRvIII Antibody Levels (mean ± SD) | P (genotype) | P (additive) | P (dominant) | P (recessive) |
|---|---|---|---|---|---|---|---|
| KM 1/3 | 3/3 | 104 | 16.7 ± 4.3 | .165 | .141 | .077 | .991 |
| 1/3 | 19 | 14.8 ± 4.0 | |||||
| 1/1 | 3 | 15.8 ± 7.7 | |||||
| GM 3/17 | 3/3 | 60 | 15.9 ± 4.5 | .017 | .021 | .151 | .007 |
| 3/17 | 56 | 16.4 ± 4.1 | |||||
| 17/17 | 10 | 19.6 ± 3.9 | |||||
| GM 5/21 | 5/5 | 63 | 16.0 ± 4.5 | .015 | .057 | .345 | .005 |
| 5/21 | 55 | 16.3 ± 4.0 | |||||
| 21/21 | 8 | 20.1 ± 4.1 | |||||
| GM 23+/− | +/+ | 34 | 15.9 ± 4.4 | .289 | .148 | .392 | .123 |
| +/− | 57 | 16.2 ± 4.5 | |||||
| −/− | 35 | 17.3 ± 4.1 | |||||
| FcγRIIa | R/R | 38 | 16.1 ± 4.3 | .849 | .568 | .609 | .674 |
| R/H | 60 | 16.5 ± 4.5 | |||||
| H/H | 28 | 16.8 ± 4.2 | |||||
| FcγRIIIa | F/F | 49 | 15.6 ± 4.1 | .066 | .358 | .070 | .407 |
| F/V | 62 | 17.3 ± 4.4 | |||||
| V/V | 15 | 15.6 ± 4.4 |